Telix Pharmaceuticals Limited Today Announces That It Has Entered Into A Licence Agreement With Eli Lilly And Company ("Lilly") Under Which Telix Is Granted Exclusive Worldwide Rights To Develop And Commercialise Radiolabelled Forms Of Lilly'S Olaratumab Antibody For The Diagnosis And Treatment Of Human Cancers. Telix'S Initial Development Focus Will Be On A Rare Type Of Cancer Known As Soft Tissue Sarcoma (Sts).Olaratumab Was Originally Developed By Lilly As A (Non-Radiolabelled) Monoclonal Antibody Targeting Platelet Derived Growth Factor Receptor Alpha (Pdgfr?). Pdgfr? Is Expressed In Multiple Tumour Types Including Sts. Sts Is Generally A Radiation Susceptible Cancer That May Be Inherently Amenable To Systemic Radionuclide Therapy And Olaratumab'S Ability To Target Pdgfr? Makes It A Highly Novel And Potentially Exciting Candidate For Use As A Radionuclide Targeting Agent. The Exclusive Worldwide Licence Will Allow Telix To Repurpose Olaratumab As A Targeting Agent For Radiopharmaceutical Imaging And Therapy Of Cancer. Olaratumab Has An Established Safety Profile That Underpins Its Potential Use As A Radionuclide Targeting Agent.Material Terms Of The Agreement Under The Terms Of The Agreement Telix Will Pay Lilly An Upfront Payment Of Us$5M (~Au$6.7M) For The Grant Of An Exclusive Licence To Lilly'S Intellectual Property Related To The Development Of A Radiolabelled Olaratumab, As Well As Access To Material For Use By Telix In Initial Pre-Clinical And Early-Phase Clinical Studies In Application To Potential Uses For The Diagnosis And Treatment Of Human Cancers.Lilly May Be Eligible For Up To Us$225M (~Au$301M) In Payments Based Upon The Achievement Of Pre-Specified Development, Regulatory And Commercial Milestones. Lilly Would Also Be Eligible To Receive Industry Standard Royalties On Net Sales. The Agreement Also Includes An Option For Lilly To Be Granted An Exclusive Licence To A Radiolabelled Companion Diagnostic Which Would Be Developed By Telix. If Exercised, Lilly Will Pay Telix Us$5M (~Au$6.7M) And Up To Us$30M (~Au$40.1M) In Potential Development Milestones, As Well As Industry Standard Royalties.The Agreement Has Typical Termination Rights For Breach And Related Corporate Issues. Telix Retains Termination Rights Typical To Licence Agreements Of This Nature To Enable The Company To Exit The Agreement Based On A Development Or Commercial Basis. Building On Telix'S Track Record In Acquiring And Commercialising AssetsTelix Group Ceo And Managing Director, Dr. Christian Behrenbruch Said, "This In-Licence Transaction With Lilly Is A Valuable
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!